Ascendis Pharma Investigational Site

New York, New York 10032

1 studies enrolling now · 7 studies all time

What they study most

2L+ Cervical Cancer, Adult Growth Hormone Deficiency, Advanced Solid Tumor, Endocrine System Diseases, Growth Hormone Deficiency, Growth Hormone Deficiency, Pediatric, Hormone Deficiency, Hypoparathyroidism, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer

Studies at this site

• A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism — Recruiting now
• A Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency — Completed
• A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial — Completed
• A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism — Completed
• A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency — Completed
• A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism — Completed
• A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies — Running, not enrolling